276 related articles for article (PubMed ID: 28871472)
1. Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.
Ur Rasheed MS; Mishra AK; Singh MP
Neurochem Res; 2017 Dec; 42(12):3353-3361. PubMed ID: 28871472
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease and CYP2D6 polymorphism in Asian populations: A meta-analysis.
Persad AS; Stedeford T; Tanaka S; Chen L; Banasik M
Neuroepidemiology; 2003; 22(6):357-61. PubMed ID: 14557687
[TBL] [Abstract][Full Text] [Related]
3. [Polymorphisms in the genes of cytochrome oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk factors for Parkinson's disease].
Durić G; Svetel M; Nikolaevic SI; Dragadević N; Gavrilović J; Kostić VS
Vojnosanit Pregl; 2007 Jan; 64(1):25-30. PubMed ID: 17304721
[TBL] [Abstract][Full Text] [Related]
4. Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism.
Bon MA; Jansen Steur EN; de Vos RA; Vermes I
Neurosci Lett; 1999 May; 266(2):149-51. PubMed ID: 10353349
[TBL] [Abstract][Full Text] [Related]
5. Association of polymorphism in cytochrome P450 2D6 and N-acetyltransferase-2 with Parkinson's disease.
Singh M; Khanna VK; Shukla R; Parmar D
Dis Markers; 2010; 28(2):87-93. PubMed ID: 20364044
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 polymorphism and Parkinson's disease susceptibility.
Sabbagh N; Brice A; Marez D; Dürr A; Legrand M; Lo Guidice JM; Destée A; Agid Y; Broly F
Mov Disord; 1999 Mar; 14(2):230-6. PubMed ID: 10091614
[TBL] [Abstract][Full Text] [Related]
7. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis.
McCann SJ; Pond SM; James KM; Le Couteur DG
J Neurol Sci; 1997 Dec; 153(1):50-3. PubMed ID: 9455978
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 phenotypes and Parkinson's disease risk: a meta-analysis.
Lu Y; Peng Q; Zeng Z; Wang J; Deng Y; Xie L; Mo C; Zeng J; Qin X; Li S
J Neurol Sci; 2014 Jan; 336(1-2):161-8. PubMed ID: 24211060
[TBL] [Abstract][Full Text] [Related]
9. P450 enzymes and Parkinson's disease: the story so far.
Riedl AG; Watts PM; Jenner P; Marsden CD
Mov Disord; 1998 Mar; 13(2):212-20. PubMed ID: 9539332
[TBL] [Abstract][Full Text] [Related]
10. Interaction between GSTM1-null and CYP2D6-deficient alleles in the pathogenesis of Parkinson's disease.
Santt O; Baranova H; Albuisson E; Bignon YJ; Lucotte G
Eur J Neurol; 2004 Apr; 11(4):247-51. PubMed ID: 15061826
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of cytochrome P450 2D6 in idiopathic Parkinson disease and diffuse Lewy body disease.
Bordet R; Broly F; Destee A; Libersa C
Clin Neuropharmacol; 1994 Oct; 17(5):484-8. PubMed ID: 9316701
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
13. Parkinson's disease, CYP2D6 polymorphism, and age.
Payami H; Lee N; Zareparsi S; Gonzales McNeal M; Camicioli R; Bird TD; Sexton G; Gancher S; Kaye J; Calhoun D; Swanson PD; Nutt J
Neurology; 2001 May; 56(10):1363-70. PubMed ID: 11376189
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM; Raimundo S; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population.
Jin TB; Ma LF; Zhang JY; Yuan DY; Sun Q; Zong TY; Geng TT; Cui YL; Kang LL; Chen C
Gene; 2013 Sep; 527(1):360-5. PubMed ID: 23644254
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 polymorphism in Parkinson's disease: the Rotterdam Study.
Harhangi BS; Oostra BA; Heutink P; van Duijn CM; Hofman A; Breteler MM
Mov Disord; 2001 Mar; 16(2):290-3. PubMed ID: 11295783
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.
Haufroid V; Hantson P
Clin Toxicol (Phila); 2015 Jul; 53(6):501-10. PubMed ID: 25998998
[TBL] [Abstract][Full Text] [Related]
18. Association of A313 G polymorphism (GSTP1*B) in the glutathione-S-transferase P1 gene with sporadic Parkinson's disease.
Vilar R; Coelho H; Rodrigues E; Gama MJ; Rivera I; Taioli E; Lechner MC
Eur J Neurol; 2007 Feb; 14(2):156-61. PubMed ID: 17250723
[TBL] [Abstract][Full Text] [Related]
19. Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro.
Wang Z; Wang L; Xu RA; Zhan YY; Huang CK; Dai DP; Cai JP; Hu GX
Drug Des Devel Ther; 2016; 10():1909-16. PubMed ID: 27354764
[TBL] [Abstract][Full Text] [Related]
20. No association between cytochrome P450 2D6 gene polymorphism and risk of acute leukemia: evidence based on a meta-analysis.
Ruan XL; Li S; Zeng XT; Xia LH; Hu Y
Chin Med J (Engl); 2013; 126(19):3750-3. PubMed ID: 24112176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
